Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 2, 2013, Pages 213-217

  Wang, Yun Xia ^a   Zheng, Shu Mei ^a   Zhang, Yong ^a   Qin, Jian Ping ^a   Lin, Hang ^a   Liu, Xiao Cong ^a   Shen, Cai Fei ^a   Jiang, Ming De ^a  

^a CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Adefovir; Chronic hepatitis B; Combination therapy; HBeAg positive; Peginterferon alfa; Poor response

Indexed keywords

ADEFOVIR; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A;

ADD ON THERAPY; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872718705     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.749513     Document Type: Article

References (26)

1. World Health Organization. Viral hepatitis: Report by the Secretariat. 2010 Mar 25
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2012;57:167-85
3. Lok A, McMahon B. Chronic hepatitis B: Update 2009 Hepatology 2009;50:661-3
4. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E Han KH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol Int 2008;2:263-83
5. Ayoub W, Keeffe E. Review article: Current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008;28: 167-77 (Pubitemid 351861968)
6. Guan R. Treatment of chronic hepatitis B infection using interferon. Med J Malaysia 2005;60:28-33
7. Shiozawa H, Nishizaki Y, Motegi S, Kojima S, Watanabe N Mine T. Non-response to previous interferon therapy and cirrhosis are risk factors for predicting breakthrough during lamivudine therapy in patients with chronic hepatitis B. Tokai J Exp Clin Med 2010;35:103-6
8. European Association For The Study Of The Liver. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56:S112-22
9. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg- negative chronic hepatitis B. Gut 2007;56:699-705 (Pubitemid 46662938)
10. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47: 428-34 (Pubitemid 351280710)
11. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: A systematic review and economic evaluation. Health Technol Assess 2006;10:iii-v; xi-xiv, 1-183
12. Jones J, Shepherd J, Baxter L, Gospodarevskaya E Hartwell D, Harris P, et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: An updated systematic review and economic evaluation. Health Technol Assess 2009;13:1-172.iii
13. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR Antonucci G, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14: 1165-74
14. Keating GM. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs 2009;69:2633-60
15. Caruntu FA, Streinu-Cercel A, Gheorghe LS Grigorescu M, Sporea I, Stanciu C, et al. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients. J Gastrointestin Liver Dis 2009;18:425-31
16. Li WC, Wang MR, Kong LB, Ren WG, Zhang YG Nan YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: A meta-analysis of controlled clinical trials. BMC Infect Dis 2011;11:165
17. Kim BK, Han KH, Ahn SH. Hepatitis B virus serology to predict antiviral response in chronic hepatitis B. Digestion 2011;84:29-34
18. Chan HL, Hui AY, Wong VW, Chim AM, Wong ML Sung JJ. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005;41:1357-64 (Pubitemid 40770289)
19. Shi Y, Wu YH, Shu ZY, Zhang WJ, Yang J, Chen Z. Interferon and lamivudine combination therapy versus lamivudine monotherapy for hepatitis B e antigen-negative hepatitis B treatment: A meta-analysis of randomized controlled trials. Hepatobiliary Pancreat Dis Int 2010;9:462-72
20. Akarca US, Ersoz G, Gunsar F, Karasu Z, Saritas E Yuce G, et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther 2004;9:325-34 (Pubitemid 38878748)
21. Calvaruso V, Mazza M, Almasio PL. Pegylated-interferonalpha
22. in clinical practice: How to manage patients suffering from side effects. Expert Opin Drug Saf 2011;10:429-35
23. Shiga K, Tanaka E, Isayama R, Mizuno T, Itoh K Nakagawa M. Chronic inflammatory demyelinating polyneuropathy due to the administration of pegylated interferon alpha-2b: A neuropathology case report. Intern Med 2012;51: 217-21
24. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR Antonucci G, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14: 1165-74
25. Ingiliz P, Valantin MA, Thibault V, Duvivier C Dominguez S, Katlama C, et al. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients. Antivir Ther 2008;13:895-900
26. Gane EJ. The Roadmap concept: Using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B. Hepatol Int 2008;2:304-7